Objective： To study the relationship between one polymorphism in the promoter of the DNA repair gene XPA and the susceptibility to lung cancer. Methods： Genotypes were determined by the PCR-restriction fragment leng...Objective： To study the relationship between one polymorphism in the promoter of the DNA repair gene XPA and the susceptibility to lung cancer. Methods： Genotypes were determined by the PCR-restriction fragment length polymorphism （PCR-RFLP） method in 310 histologically-confirmed lung cancer cases and 341 age and sex frequency-matched cancer-free controls. Results： The XPA A23G genotype frequencies were 27.1% （AA）, 42.9% （AG）, and 30.0% （GG） in case patients and21.1% （AA）, 5218% （AG）, and 26.1% （C-G） in control subjects. Multivariate logistic regression analysis revealed that individuals carrying at least one 23G variant allele （AG ＋ GG genotypes） had a significantly decreased risk for lung cancer （adjusted OR = 0.66; 95 % CI = 0.44- 0.98） compared with the wild-type genotype （23AA）. Stratified analysis showed that the protective effect was more evident in subjects with a family history of cancer. Conclusion： These results suggest that the XPA A23G polymorphism may have a role in lung cancer susceptibility in this study population.展开更多
目的：DNA修复能力与肿瘤细胞对铂类药物的敏感性密切相关。该研究利用一种新型单核苷酸多态性（SNP）的检测方法，探讨DNA修复基因XPA的SNP与非小细胞肺癌（NSCLC）患者对顺铂（ciaplatin）或卡铂（carboplatin）为主的化疗方案敏感性...目的：DNA修复能力与肿瘤细胞对铂类药物的敏感性密切相关。该研究利用一种新型单核苷酸多态性（SNP）的检测方法，探讨DNA修复基因XPA的SNP与非小细胞肺癌（NSCLC）患者对顺铂（ciaplatin）或卡铂（carboplatin）为主的化疗方案敏感性的关系。方法：经病理学确诊的晚期NSCLC患者96例，采用顺铂或卡铂为主的方案化疗，2～3个周期后进行临床疗效评价。根据cDNA芯片原理制作一种目的基因芯片，利用双色荧光探针杂交进行咒蹦的A23G多态的基因分型，比较不同基因型对化疗敏感性的影响。组间比较采用χ^2检验，比值比（OR）及其95％可信区间（CI）由logistic回归模型计算。结果：成功进行基因分型，野生型、杂合型和突变型的叠加荧光分别显示为绿色、黄色和红色。携带咒蹦23A／A、A／G和G／G基因型的患者，化疗有效率（完全缓解＋部分缓解）分别为35．7％、46．9％和16．7％，差异有显著性统计学意义（P〈0．05）；携带G／G基因型患者的化疗失败风险是携带至少1个A等位基因（A／G和A/A基因型）个体的3．57倍；但G等位基因携带者的疗效与A等位基因携带者的相似，差异无统计学意义（30．9％ vs 41．7％，P=0．2045）。结论：该芯片检测方法准确、高通量且价格低廉，适用于大规模样本SNP调查；XPA基因多态与NSCLC患者对铂类药物化疗的敏感性相关。展开更多
文摘Objective： To study the relationship between one polymorphism in the promoter of the DNA repair gene XPA and the susceptibility to lung cancer. Methods： Genotypes were determined by the PCR-restriction fragment length polymorphism （PCR-RFLP） method in 310 histologically-confirmed lung cancer cases and 341 age and sex frequency-matched cancer-free controls. Results： The XPA A23G genotype frequencies were 27.1% （AA）, 42.9% （AG）, and 30.0% （GG） in case patients and21.1% （AA）, 5218% （AG）, and 26.1% （C-G） in control subjects. Multivariate logistic regression analysis revealed that individuals carrying at least one 23G variant allele （AG ＋ GG genotypes） had a significantly decreased risk for lung cancer （adjusted OR = 0.66; 95 % CI = 0.44- 0.98） compared with the wild-type genotype （23AA）. Stratified analysis showed that the protective effect was more evident in subjects with a family history of cancer. Conclusion： These results suggest that the XPA A23G polymorphism may have a role in lung cancer susceptibility in this study population.
文摘目的：DNA修复能力与肿瘤细胞对铂类药物的敏感性密切相关。该研究利用一种新型单核苷酸多态性（SNP）的检测方法，探讨DNA修复基因XPA的SNP与非小细胞肺癌（NSCLC）患者对顺铂（ciaplatin）或卡铂（carboplatin）为主的化疗方案敏感性的关系。方法：经病理学确诊的晚期NSCLC患者96例，采用顺铂或卡铂为主的方案化疗，2～3个周期后进行临床疗效评价。根据cDNA芯片原理制作一种目的基因芯片，利用双色荧光探针杂交进行咒蹦的A23G多态的基因分型，比较不同基因型对化疗敏感性的影响。组间比较采用χ^2检验，比值比（OR）及其95％可信区间（CI）由logistic回归模型计算。结果：成功进行基因分型，野生型、杂合型和突变型的叠加荧光分别显示为绿色、黄色和红色。携带咒蹦23A／A、A／G和G／G基因型的患者，化疗有效率（完全缓解＋部分缓解）分别为35．7％、46．9％和16．7％，差异有显著性统计学意义（P〈0．05）；携带G／G基因型患者的化疗失败风险是携带至少1个A等位基因（A／G和A/A基因型）个体的3．57倍；但G等位基因携带者的疗效与A等位基因携带者的相似，差异无统计学意义（30．9％ vs 41．7％，P=0．2045）。结论：该芯片检测方法准确、高通量且价格低廉，适用于大规模样本SNP调查；XPA基因多态与NSCLC患者对铂类药物化疗的敏感性相关。
